{
    "2021-08-13": [
        [
            {
                "time": "",
                "original_text": "股获买入评级 最新:贝达药业",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "益方生物答科创板二轮问询，专利纠纷和商业秘密纠纷等被关注",
                "features": {
                    "keywords": [
                        "益方生物",
                        "科创板",
                        "专利纠纷",
                        "商业秘密纠纷"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "26家药企上半年八成净利润增长 两家公司重磅新药即将报产",
                "features": {
                    "keywords": [
                        "药企",
                        "净利润增长",
                        "新药报产"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "西部证券维持贝达药业买入评级，2021年半年报点评：业绩高基数下持续增长，管线取得阶段性进展",
                "features": {
                    "keywords": [
                        "西部证券",
                        "贝达药业",
                        "买入评级",
                        "业绩增长",
                        "管线进展"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}